Doc. MUDr. Mgr. Marek Mráz, Ph.D.

Email:                           

 

 

 

Education

o   PhD in Oncology; Faculty of Medicine; Masaryk University

o   MUDr./M.D. in General Medicine; Faculty of Medicine; Masaryk University

o   Mgr./MSc. in Molecular Biology; Faculty of Science, Masaryk University

 

Professional experiences

o  since 2015 Associate Professor of Oncology, Masaryk University and University Hospital Brno

 

o  since 2015  Member of Early Career Advisory Committee of the European Haematology Association

 

o   2011-2014 Post-Doctoral Research Fellow,University of California-San Diego, San Diego, US

Laboratory of CLL Biology (supervisor Prof. T.J. Kipps, MD) 

 

o   2009-2010 Post-Doctoral Research Fellow, Mayo Clinic, Dept. of Hematology, Rochester, US

Laboratory of Lymphoma Biology (supervisor Prof. T. Witzig, MD and Prof. G. Nowakowski, MD)

Laboratory of CLL Biology (supervisor Prof. C. Zent, MD) 

 

o   Since 2006, Dept of Internal Medicine -Hematooncology, University Hospital Brno

Laboratory of CLL Biology (Research group of Prof. S. Pospisilova, PhD and Prof. J. Mayer, MD)

 

Awards and achievements

o   2016 - J.V. Kostir Award for excellence in science (Czech Soc of Biochemistry and Molecular Biology)

o   2016 - Award from the Purkyne Foundation (Praque)

o   2015 – Award of the rector of Masaryk University for excellence in science for young investigators

o   2015 - Award of the Czech Society for Oncology for the most influential scientific publication in 2014

o   2014 – Discovery Award for Innovation in Biomedicine (Novartis)

o   2014- European Hematology Association Research Award

o   2014- SoMoPro Fellowship

o   2012 – Achievement Award for the best abstract at 54th American Society of Hematology Annual Meeting

o   2012 – Best presentation at the Young Investigators Meeting in CLL (Cologne, Germany)

o   2011 - Award of the Ministry of Education of Czech Rep. for outstanding student of PhD programs

o   2011,  2008 - Award  „Young Czech Hematologists“-awarded by committee of the Prague Hematology Day

o   2010 - Award of the Faculty of Medicine for the most influential scientific publication in 2009

o   2009, 2008 - Award of the rector of Masaryk University for the most successful student of PhD programs

o   2009 - Travel Grant provided by the organizing committee of the 13th EHA, 14th EHA, and 51ST ASH Meeting

o   2009 - 1st Prize for Young Scientist in Biology and Biochemistry awarded by Sigma  - Aldrich

 

Membership

o   American Association for Cancer Research

o   European Research Initiative on CLL (ERIC)

o   European Hematology Association (EHA)

o   European Leukemia Net (ELN)

o   Czech Society of Hematology

o   Czech Leukemia Study Group for Life (CELL)

o   Czech Society of Oncology

o   Czech Society for Biochemistry and Molecular Biology

o   Genetic Society of J.G. Mendel 

 

Peer-Reviewer for Journals

o    Blood

o    Leukemia

o    Haematologica

o    Leukemia and Lymphoma

o    Stem Cells

o    BMC Cancer

o    Plos One

 

Teaching activities

o    Faculty of Medicine, Masaryk University, Brno

o     Faculty of Sciences, Masaryk University, Brno

 

Other activities:

o   Member of Early Career Advisory Committee of the European Haematology Association

o   Instructor at EMBL microRNA workshop (2011, 2015)

 

PUBLICATIONS (updated 11/2016)

o   PUBLICATIONS WITH IMPACT FACTOR: 26

o   Invited book chapters: 6 (1x international book-Elsevier, 5x Czech book)

o   TOTAL IMPACT FACTOR: 148,3

o   H- INDEX: 15 (WOS)

 

SELECTED PUBLICATIONS:

o   Gabriela Pavlasova, Marek Borsky, Vaclav Seda, Katerina Cerna, Jitka Osickova, Michael Doubek, Jiri Mayer, Raffaele Calogero, Martin Trbusek, Sarka Pospisilova, Matthew S. Davids, Thomas J. Kipps, Jennifer R. Brown, Marek Mraz. Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood.  2016. 1 Aug [epub ahead of print]. Impact factor: 11,5; corresponding author

 

o   Musilova K, Mraz M. MicroRNAs in B cell lymphomas: How a complex biology gets more complex. Leukemia. In press, accepted Dec 2014 [Epub ahead of print]Impact factor: 9,4; corresponding author

 

o   Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 genes. Blood. 2014 May 1. [Epub ahead of print] Impact factor: 9,8

 

o   Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. MicroRNA-155 Influences B-cell Receptor Signaling And Associates With Aggressive Disease In Chronic Lymphocytic Leukemia. Blood. 2014. Impact factor: 9,8

 

o   Dolezalova D, Mraz M*, Barta T, Plevova K, Vinarsky V, Holubcova Z, Jaros J, Dvorak P, Pospisilova S, Hampl A. MicroRNAs Regulate p21(Waf1/Cip1) Protein Expression and the DNA Damage Response in Human Embryonic Stem Cells.Stem Cells. 2012; 30(7):1362-72.Impact factor: 7,8;shared first author and corresponding author.

 

o   Mraz M*, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, Verner J, Doubek M, Brychtova Y, Trbusek M, Hampl A, Mayer J, Pospisilova S.MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012 Mar 1;119(9):2110-3.Impact factor: 10,6; first and corresponding author.

 

o   Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155(1):53-64.; Impact factor: 4,9

 

o   Mraz M,Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S.  miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23(6):1159-63.; Impact factor: 8.9

 

o   Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, Savvulidi F, Kokavec J, Necas E, Berkova A, Obrtlikova P, Karban J, Mraz M, Pospisilova S, Mayer J, Trneny M, Zavadil J, Stopka T. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011;117(14):3816-25.; Impact factor: 10,6

 

o   Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, Vranova V, Mraz M, Skuhrova Francova H, Doubek M, Brychtova Y, Kuglik P, Pospisilova S, Mayer J. Missense Mutations Located in Structural p53 DNA-binding Motifs Are Associated with Extremely Poor Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2011;29(19):2703-8.; Impact factor: 18,9

PATENT: The use of miR-34a and miR-150 for prognostication and prediction of response in B cell malignancies, Patent number: CZ 306080 (date 7/2016)

 

Invited book chapters

o   Dolezalova D, Mraz M, Hampl A. miRNA in Embryonic Stem Cells. In MICRORNA IN REGENERATIVE MEDICINE (Elsevier Inc.)

Devan J, Mraz M. Buněčná biologie folikulárního lymfomu. Mlada Fronta. 2016 [in press](chapter in czech language)

o   Mráz M, Musilová K, Mayer J, Pospíšilová S. Úloha microRNA v patogenezi b-buněčných lymfomů. MikroRNA v Onkologii. Galén 2012.(chapter in czech language)

o   Mráz M,  Mayerová V, Černá K, Doležalová D, Musilová K, Mayer J, Pospíšilová Š. Úloha microRNA u chronické lymfocytární leukémie. MikroRNA v Onkologii. Galén 2012.(chapter in czech language)

o   Mráz M, Pospíšilová Š. Genová terapie u hematologických onemocnění: historie a budoucnost. Molekulární hematologii . Galén 2012.(chapter in czech language)

o   Trbušek M, Mráz M, Pospíšilová Š, Doubek M. Molekulární patogeneze B-buněčné chronické lymfocytární leukémie (B- CLL) . Molekulární hematologii . Galén 2012.(chapter in czech language)

 

Publications in czech medical journals

o   Mraz M, Doubek M,  Mayer J,  Pospisilova S. Inhibici signalizace B-buněčným receptorem: první cílená léčba u chronické lymfatické leukémie a dalších B-buněčných lymfomů. Klinická onkologie. 2013; in press (review article in czech language)

o   Mraz M,Trbusek M, Dolezalova D, Malcikova J, Supikova J, Stano-Kozubík K, Kantorova B,  Mayer J,  Pospisilova S. Identifikace patogeneticky významných mutací u chronické lymfatické leukémie pomocí „sekvenování nové generace“. Transfuze a hematologie dnes. 2012; 18: 72-75 (review article in czech language)

o   Mráz M,Pavlová Š, Malčíková J, Malinová K, Mayer J, Pospíšilová, Š. Molekulární patogeneze chronické lymfocytární leukémie. Transfuze a hematologie dnes.2010 Suppl 1: 16-20(review article in czech language)

o   Mráz M,Pospíšilová Š, Mayer J.MicroRNA v patogenezi chronické lymfocytární leukémie a jejich prognostický význam. Transfuze a hematologie dnes. 2010 Suppl 1: 33-35.(review article in czech language)

o   Pospíšilová Š, Malinová K, Mráz M, Mayer J. MicroRNA – malé molekuly s velkým významem (nejen) u hematologických malignit.Transfuze a hematologie dnes. 2008; 14: 180-187.(review article in czech language)

o   Létalová E, Doubek M, Folber F, Verner J, Mráz M, Pospíšilová Š, Mayer J. Mikroprostředí kostní dřeně a jeho role v patogenezi leukemií. Transfuze Hematol. Dnes. 2011;4: 171-176.(review article in czech language)

 

 


zde může být Vaše reklama logo Zbrojovky Brno logo Lékaři bez hranic
Kalendář akcí
říjen
Po Út St Čt So Ne
1
2345678
9101112131415
16171819202122
23 242526 272829
3031
2017
Anketa
Setkali jste se ve FN Brno s korupčním jednáním?



CZ ENG DE

změnit velikost písma

Jihlavská 20, 625 00 Brno
+420 532 23 1111

NIAHOSM ISO 9001:2008 ISO 14001:2001